Featured news
Nanologica’s Interim Report Jan-Sep 2022
11 November, 2022
Nanologica AB’s Interim Report Jan-Sep 2022 The auditor’s report Q3 2022 (Swedish) Report presentation Q3 2022 FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 401 (2,119) and for the nine-month period to TSEK 881 (12,238) The operating result for the quarter amounted to TSEK -9,610 (-11,718) and for the nine-month period to TSEK -37,599 (-26,581) Result after tax for the quarter amounted to TSEK -10,988 (-12,546) and for the nine-month period
5 Quick Questions with Katarina Alenäs
27 October, 2022
Katarina Alenäs, SVP Chromatography Nanologica AB Who is Katarina Alenäs? I have a M.Sc. in Chemical Engineering and a B.Sc. in Pharmaceutical Sciences and have spent most of my professional career within chromatography which is an area very close to my heart. Before joining Nanologica, I was the Country General Manager at Agilent Technologies Sweden, and before that I have been Product Manager Shimadzu HPLC/LCMS and I started my career as a Development Engineer of
MVIC Inhalation Symposium
11 October, 2022
October 12-13, Nanologica will take part of the MVIC Inhalation Symposium in Lund where Nanologica’s Senior Scientist Dr Georgia Pilkington will give a speach on Evaluation of Nanoporous Particles as a Delivery Vehicle for Inhaled Drugs. MVIC Symposium in Lund 12-13 October 2022
Nanologica Raises MSEK 79,8 in Rights Issue
10 October, 2022
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Nanologica AB (publ) (”Nanologica” or the “Company”) today announces the outcome of the new shares issue with preferential rights for Nanologica’s existing shareholders (the